Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172)
Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172)
Concern about late adverse effects of cranial radiotherapy (XRT) has led to alternative approaches to eliminate leukaemia from the central nervous system (CNS) in childhood acute lymphoblastic leukaemia (ALL). The Medical Research Council UKALL XI trial recruited 2090 children with ALL between 1990 and 1997. Median follow-up is 7 years 9 months; event-free survival (EFS) and overall survival were 63·1% and 84·6%, respectively, at 5 years and 59·8% and 79·4% at 10 years. The isolated CNS relapse rate was 7·0% at 10 years. Patients were randomized for CNS-directed therapy within white blood cell (WBC) groups. For WBC <50 × 109/l, high-dose intravenous methotrexate (HDMTX) (6–8 g/m2) with intrathecal methotrexate (ITMTX) was compared with ITMTX alone, and was significantly better at preventing isolated and combined CNS relapse, but non-CNS relapses were similar. There was no significant difference in EFS at 10 years, 64·1% [95% confidence interval (CI) 60·4–67·8] with HDMTX plus ITMTX, and 63·0% (95% CI 59·5–66·5) with ITMTX alone. For WBC ?50 × 109/l, HDMTX with ITMTX was compared with XRT and a short course of ITMTX. CNS relapses were significantly fewer with XRT, but there was a non-significant increase in non-CNS relapses. EFS was not significantly different, being 55·2% (95% CI 47·8–62·6) at 10 years with XRT and 52·1% (95% CI 44·8–59·4) with HDMTX plus ITMTX.
childhood acute lymphoblastic leukaemia, risk stratified, cns therapy, randomized study, ukall xi
33-46
Hill, Frank G.
d7b89ae5-ee73-4f2a-aadc-3ba96d4f18f8
Richards, Sue
c6716b3c-db48-40e3-a714-219bb8aa91c5
Gibson, Brenda
91673809-7015-4a25-b310-2dd5cb7c154a
Hann, Ian
acc48ebf-86d1-4ce5-a384-4f628d5d9031
Lilleyman, John
a56e5148-89cc-408d-ba7d-007576c174b2
Kinsey, Sally
8463aaab-8253-4072-9492-e7fcce7bec15
Mitchell, Christopher
de7a4456-f392-4fa0-b2da-dcb9f5da82ed
Harrison, Christine J.
52da7673-509c-4b88-b92e-0c021c9c7d3e
Eden, Osborn B.
a1294d66-3690-4710-9b0e-508d4c2d6bf1
January 2004
Hill, Frank G.
d7b89ae5-ee73-4f2a-aadc-3ba96d4f18f8
Richards, Sue
c6716b3c-db48-40e3-a714-219bb8aa91c5
Gibson, Brenda
91673809-7015-4a25-b310-2dd5cb7c154a
Hann, Ian
acc48ebf-86d1-4ce5-a384-4f628d5d9031
Lilleyman, John
a56e5148-89cc-408d-ba7d-007576c174b2
Kinsey, Sally
8463aaab-8253-4072-9492-e7fcce7bec15
Mitchell, Christopher
de7a4456-f392-4fa0-b2da-dcb9f5da82ed
Harrison, Christine J.
52da7673-509c-4b88-b92e-0c021c9c7d3e
Eden, Osborn B.
a1294d66-3690-4710-9b0e-508d4c2d6bf1
Hill, Frank G., Richards, Sue, Gibson, Brenda, Hann, Ian, Lilleyman, John, Kinsey, Sally, Mitchell, Christopher, Harrison, Christine J. and Eden, Osborn B.
(2004)
Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172).
British Journal of Haematology, 124 (1), .
(doi:10.1046/j.1365-2141.2003.04738.x).
Abstract
Concern about late adverse effects of cranial radiotherapy (XRT) has led to alternative approaches to eliminate leukaemia from the central nervous system (CNS) in childhood acute lymphoblastic leukaemia (ALL). The Medical Research Council UKALL XI trial recruited 2090 children with ALL between 1990 and 1997. Median follow-up is 7 years 9 months; event-free survival (EFS) and overall survival were 63·1% and 84·6%, respectively, at 5 years and 59·8% and 79·4% at 10 years. The isolated CNS relapse rate was 7·0% at 10 years. Patients were randomized for CNS-directed therapy within white blood cell (WBC) groups. For WBC <50 × 109/l, high-dose intravenous methotrexate (HDMTX) (6–8 g/m2) with intrathecal methotrexate (ITMTX) was compared with ITMTX alone, and was significantly better at preventing isolated and combined CNS relapse, but non-CNS relapses were similar. There was no significant difference in EFS at 10 years, 64·1% [95% confidence interval (CI) 60·4–67·8] with HDMTX plus ITMTX, and 63·0% (95% CI 59·5–66·5) with ITMTX alone. For WBC ?50 × 109/l, HDMTX with ITMTX was compared with XRT and a short course of ITMTX. CNS relapses were significantly fewer with XRT, but there was a non-significant increase in non-CNS relapses. EFS was not significantly different, being 55·2% (95% CI 47·8–62·6) at 10 years with XRT and 52·1% (95% CI 44·8–59·4) with HDMTX plus ITMTX.
This record has no associated files available for download.
More information
Submitted date: May 2003
Published date: January 2004
Keywords:
childhood acute lymphoblastic leukaemia, risk stratified, cns therapy, randomized study, ukall xi
Identifiers
Local EPrints ID: 26385
URI: http://eprints.soton.ac.uk/id/eprint/26385
ISSN: 0007-1048
PURE UUID: ac5b9d52-7f5e-414c-84de-07ae8d45e415
Catalogue record
Date deposited: 21 Apr 2006
Last modified: 15 Mar 2024 07:10
Export record
Altmetrics
Contributors
Author:
Frank G. Hill
Author:
Sue Richards
Author:
Brenda Gibson
Author:
Ian Hann
Author:
John Lilleyman
Author:
Sally Kinsey
Author:
Christopher Mitchell
Author:
Christine J. Harrison
Author:
Osborn B. Eden
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics